Literature DB >> 22014691

Nonpharmacological treatment of Alzheimer disease.

Clive Ballard1, Zunera Khan, Hannah Clack, Anne Corbett.   

Abstract

OBJECTIVE: To review the key nonpharmacological treatment approaches to the cognitive and functional symptoms of Alzheimer disease (AD).
METHODS: We searched and critically analyzed the most recent relevant literature pertaining to the nonpharmacological treatment of AD.
RESULTS: There is evidence from a modest number of well-conducted randomized controlled trials (RCTs) that various nonpharmacological approaches, including cognitive training, cognitive rehabilitation, and cognitive stimulation therapy (CST), confer modest but significant benefits in the treatment of cognitive symptoms in people with AD, and that there may be additive benefits in combination with cholinesterase inhibitor therapy. Cognitive rehabilitation also appears to result in functional benefits in AD. The modest number of RCTs focusing on cognitive training in AD is consistent with the results of larger cognitive training trials in healthy older people. however, there is no convincing evidence of any benefits associated with brain training games.
CONCLUSION: An emerging evidence base indicates that different approaches to cognitive training and cognitive stimulation in people with AD confer modest but significant benefits. The best evidence base is for CST, although this approach is labour-intensive, and requires further evaluation of cost-effectiveness. There is currently no evidence that brain training games provide any significant benefit to people with AD.

Entities:  

Mesh:

Year:  2011        PMID: 22014691     DOI: 10.1177/070674371105601004

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  16 in total

1.  Positive argument for debate in J Neural Transmission: Alzheimer's disease: are we intervening too late? Yes, by years if not decades.

Authors:  Thomas B Shea; Ruth Remington
Journal:  J Neural Transm (Vienna)       Date:  2012-07-11       Impact factor: 3.575

2.  Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies.

Authors:  Anna Borisovskaya; Marcella Pascualy; Soo Borson
Journal:  Curr Psychiatry Rep       Date:  2014-09       Impact factor: 5.285

3.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

4.  A randomized trial of a community-based cognitive intervention for obese senior adults.

Authors:  Cornelia Beck; Jennifer Kleiner Fausett; Rebecca A Krukowski; Carol E Cornell; T Elaine Prewitt; Shelly Lensing; Zoran Bursac; Holly C Felix; ShaRhonda Love; Graham McDougall; Delia Smith West
Journal:  J Aging Health       Date:  2012-12-16

5.  Mildronate improves cognition and reduces amyloid-β pathology in transgenic Alzheimer's disease mice.

Authors:  Ulrika Beitnere; Thomas van Groen; Ashish Kumar; Baiba Jansone; Vija Klusa; Inga Kadish
Journal:  J Neurosci Res       Date:  2013-11-22       Impact factor: 4.164

6.  Non-Pharmacologic Interventions for Persons with Dementia.

Authors:  Marla Berg-Weger; Daniel B Stewart
Journal:  Mo Med       Date:  2017 Mar-Apr

7.  Alzheimer's disease: a clinical practice-oriented review.

Authors:  Luísa Alves; Ana Sofia A Correia; Rita Miguel; Paulo Alegria; Paulo Bugalho
Journal:  Front Neurol       Date:  2012-04-20       Impact factor: 4.003

8.  Are the effects of a non-drug multimodal activation therapy of dementia sustainable? Follow-up study 10 months after completion of a randomised controlled trial.

Authors:  Katharina Luttenberger; Benjamin Hofner; Elmar Graessel
Journal:  BMC Neurol       Date:  2012-12-05       Impact factor: 2.474

9.  Use of physical and intellectual activities and socialization in the management of cognitive decline of aging and in dementia: a review.

Authors:  Myuri Ruthirakuhan; Angela C Luedke; Angela Tam; Ankita Goel; Ayaz Kurji; Angeles Garcia
Journal:  J Aging Res       Date:  2012-12-31

10.  Structural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous Trifluoroethanol.

Authors:  Christina Dammers; Lothar Gremer; Kerstin Reiß; Antonia N Klein; Philipp Neudecker; Rudolf Hartmann; Na Sun; Hans-Ulrich Demuth; Melanie Schwarten; Dieter Willbold
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.